Show simple item record

dc.contributor.authorXiao, M
dc.contributor.authorXu, D
dc.contributor.authorCraig, MT
dc.contributor.authorPelkey, KA
dc.contributor.authorChien, C
dc.contributor.authorShi, Y
dc.contributor.authorZhang, J
dc.contributor.authorResnick, S
dc.contributor.authorPletnikova, O
dc.contributor.authorSalmon, D
dc.contributor.authorBrewer, J
dc.contributor.authorEdland, S
dc.contributor.authorWegiel, J
dc.contributor.authorTycko, B
dc.contributor.authorSavonenko, A
dc.contributor.authorReeves, RH
dc.contributor.authorTroncoso, JC
dc.contributor.authorMcBain, CJ
dc.contributor.authorGalasko, D
dc.contributor.authorWorley, PF
dc.date.accessioned2017-05-24T15:25:46Z
dc.date.issued2017-03-23
dc.description.abstractMemory loss in Alzheimer’s disease (AD) is attributed to pervasive weakening and loss of synapses. Here, we present findings supporting a special role for excitatory synapses connecting pyramidal neurons of the hippocampus and cortex with fast-spiking parvalbumin (PV) interneurons that control network excitability and rhythmicity. Excitatory synapses on PV interneurons are dependent on the AMPA receptor subunit GluA4, which is regulated by presynaptic expression of the synaptogenic immediate early gene NPTX2 by pyramidal neurons. In a mouse model of AD amyloidosis, Nptx2-/- results in reduced GluA4 expression, disrupted rhythmicity, and increased pyramidal neuron excitability. Postmortem human AD cortex shows profound reductions of NPTX2 and coordinate reductions of GluA4. NPTX2 in human CSF is reduced in subjects with AD and shows robust correlations with cognitive performance and hippocampal volume. These findings implicate failure of adaptive control of pyramidal neuron-PV circuits as a pathophysiological mechanism contributing to cognitive failure in AD.en_GB
dc.description.sponsorshipDNA.This study was supported by NIMH MH100024 (PFW), (R35 NS-097966) (PFW), P50 AG005146-27 (PFW, JCT), Down Syndrome Research and Treatment Foundation and Research Down Syndrome (MX and RR), NIA AG05131 (DS, SE, DG), Alzheimer’s Disease Drug Discovery Foundation (DX, DG) and in part by the Intramural Research Program, National Institute on Aging, and National Institutes on Child Health and Development, NIH.en_GB
dc.identifier.citationVol. 6, article e23798en_GB
dc.identifier.doi10.7554/eLife.23798
dc.identifier.urihttp://hdl.handle.net/10871/27683
dc.language.isoenen_GB
dc.publishereLife Sciences Publicationsen_GB
dc.rightsCopyright Xiao et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited: https://creativecommons.org/licenses/by/4.0/en_GB
dc.subjectimmediate early geneen_GB
dc.subjectinhibitory neuronen_GB
dc.subjectdementiaen_GB
dc.subjectAlzheimer's diseaseen_GB
dc.titleNPTX2 and cognitive dysfunction in Alzheimer’s Diseaseen_GB
dc.typeArticleen_GB
dc.date.available2017-05-24T15:25:46Z
dc.contributor.editorChao, MVen_GB
dc.identifier.issn2050-084X
dc.descriptionThis is the final version of the article. Available from eLife Sciences Publications via the DOI in this record.en_GB
dc.identifier.journaleLifeen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright Xiao et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited: https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's licence is described as Copyright Xiao et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited: https://creativecommons.org/licenses/by/4.0/